"Pendulum Therapeutics Announces Formation Of Scientific And Medical Advisory Boards"
Pendulum Therapeutics, an evidence-based microbiome company, announced today the formation of its Scientific Advisory Board and Medical Advisory Board. The two boards comprise experts in metabolic disease, computational biology, genetics and microbiology who are faculty members at world-leading medical institutions. “I’ve long believed that the next major medical breakthroughs would come from analyzing and deciphering the complex world of the microbiome through rigorous excellent DNA science,” said Eric Schadt, PhD, dean of precision medicine at the Icahn School of Medicine at Mount Sinai and chief executive officer of Sema4. He added, “Pendulum Therapeutics has built a microbiome discovery and development platform that stands at the center of this new field of medical innovation and is poised to revolutionize how we address chronic diseases through paradigm-shifting medical innovations.”
— Eric Schadt, PhD, Dean, Precision Medicine, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Chief Executive Officer, Sema4